Ocular Therapeutix, Inc.
OCULDrugs in Pipeline
13
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How OCUL's past catalysts played out
OTX-TKI (axitinib implant)
Neovascular Age-Related Macular Degeneration
Punctum Plug
Post Ocular Surgical Inflammation and Pain
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
Non-Proliferative Diabetic Retinopathy
Ophthalmic Insert
Open Angle Glaucoma and Ocular Hypertension
Dextenza Ophthalmic Insert
Cataract
Travoprost
Open Angle Glaucoma
Dexamethasone, 0.4mg
Allergic Conjunctivitis
OTX-TP
Glaucoma
OTX-TIC low dose Travoprost Intracameral Implant
Open Angle Glaucoma
OTX-CSI
Dry Eye Disease
OTX-DED
Dry Eye
OTX-DP (Dexamethasone punctum plug)
Ocular Inflammation and Pain
Controlled Insertion
Dry Eye Syndromes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain | - | - |
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy | - | - |
Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension | - | - |
Dextenza Ophthalmic Insert | Phase 3 | Cataract | - | - |
Travoprost | Phase 3 | Open Angle Glaucoma | - | - |
Dexamethasone, 0.4mg | Phase 3 | Allergic Conjunctivitis | - | - |
OTX-TP | Phase 2 | Glaucoma | - | - |
OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma | - | - |
OTX-CSI | Phase 2 | Dry Eye Disease | - | - |
OTX-DED | Phase 2 | Dry Eye | - | - |
OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain | - | - |
Controlled Insertion | Phase 2 | Dry Eye Syndromes | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ocular Therapeutix, Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in Ocular Therapeutix, Inc.'s (OCUL) pipeline across Phase 3, Phase 2. Its lead program is OTX-TKI (axitinib implant) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ocular Therapeutix, Inc.'s next FDA catalyst?→
Ocular Therapeutix, Inc.'s (OCUL) next tracked catalyst is a Phase 3 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCUL biotech catalysts?→
Add OCUL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocular Therapeutix, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.